Cappuccio F P, Markandu N D, Singer D R, Buckley M G, Miller M A, Sagnella G A, MacGregor G A
Department of Medicine, St. George's Hospital Medical School, London, England.
Am J Hypertens. 1991 Apr;4(4 Pt 1):297-302. doi: 10.1093/ajh/4.4.297.
Twelve patients with essential hypertension who were already on treatment with the long-acting calcium antagonist amlodipine (5 mg once daily) were entered into a double-blind, randomized crossover study of the addition of one month's treatment with either bendrofluazide (5 mg once daily) or matching placebo. The addition of bendrofluazide did not cause any statistically significant fall in the supine blood pressure compared to treatment with placebo (147.6/90.1 +/- 4.8/2.8 v 150.8/92.6 +/- 4.3/2.3 mm Hg, respectively). Plasma potassium was significantly lower on bendrofluazide as compared to placebo (3.11 +/- 0.14 v 3.62v +/- 0.13 mmol/L, P less than .001) and 10 of 12 patients had a fall in plasma potassium while on diuretic. The results of this study suggest that a thiazide diuretic has little additive effect on blood pressure in patients already on the long-acting dihydropyridine amlodipine, and may cause hypokalemia.
12名正在接受长效钙拮抗剂氨氯地平(每日1次,每次5毫克)治疗的原发性高血压患者进入一项双盲、随机交叉研究,分别加用苄氟噻嗪(每日1次,每次5毫克)或匹配的安慰剂进行为期1个月的治疗。与安慰剂治疗相比,加用苄氟噻嗪并未使仰卧位血压出现任何具有统计学意义的下降(分别为147.6/90.1±4.8/2.8与150.8/92.6±4.3/2.3毫米汞柱)。与安慰剂相比,苄氟噻嗪治疗组的血浆钾显著降低(分别为3.11±0.14与3.62±0.13毫摩尔/升,P<0.001),12名患者中有10名在使用利尿剂期间血浆钾下降。本研究结果表明,噻嗪类利尿剂对已接受长效二氢吡啶类氨氯地平治疗的患者的血压几乎没有附加作用,且可能导致低钾血症。